Abstract
Protein kinases form one of the largest families of proteins encoded in the human genome, and these enzymes have critical roles in controlling all cellular processes. The abnormal phosphorylation state of proteins is the cause or consequence of many diseases and, for this reason, protein kinases have become attractive drug targets for the treatment of cancer, diabetes, hypertension, inflammation, and other disorders (1–3).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ishii H., Jirousek M. R., Koya D., Takagi C., Xia P., Clermont A., Lermont A., Bursell S. E., Kern T. S., Ballas L. M., Heath W. F., Stramm L. E., Feener E. P., and King G. L. (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor. Science 272, 728–731.
Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., Tamakawa H., Yamagami K., Inui J., Maekawa M., and Narumiya S. (1997) Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990–994.
Badger A. M., Bradbeer J. N., Votta B., Lee J. C., Adams J. L., and Griswold D. E. (1996) Phamacological profile of SB 203580, a selective inhibitor of cytokine suppessive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279, 1453–1461.
Cross D. A. E., Alessi D. R., Cohen P., Andjelkovic M., and Hemmings B. A. (1995) Inhibition of glycogen-synthase kinase-3 by insulin is mediated by protein kinase B. Nature 378, 785–789.
Lee J. C. and Young P. R. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739–746.
Cuenda A., Rouse J., Doza Y. N., Meier R., Young P. R., Cohen P., and Lee J. C. (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364, 229–233.
Goedert M., Cuenda A., Craxton M., Jakes R., and Cohen P. (1997) Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3/MKK6; comparison of its substrate specificity with that of other SAP kinases. EMBO J. 16, 3563–3571.
Eyers P. A., Craxton M., Morrice N., Cohen P., and Goedert M. (1998) Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol. 5, 321–328.
Cohen P. (1997) The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol. 7, 353–361.
Deak M., Clifton A. D., Lucocq J. M., and Alessi D. R. (1998) Mitogen-and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may itself mediate activation of CREB. EMBO J. 17, 4426–4441.
New L., Jiang Y., Zhao M., Liu K., Zhu W., Flood L. J., Kato Y., Parry G. C. N., and Han J. H. (1998) PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J. 17, 3372–3384.
Laemmli U. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 277, 680–685.
Alessi D. R., Cuenda A., Cohen P., Dudley D. T., and Saltiel A. R. (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase. in vitro and in vivo. J. Biol. Chem. 270, 27,489–27,494.
Ballou L. M., Luther H., and Thomas G. (1991) MAP2 kinase and 70K-S6 kinase lie on distinct signalling pathways. Nature 349, 348–350.
Price D. J., Grove J. R., Clavo V., Avruch J., and Bierer B. E. (1992) Rapamycin-induced inhibition of the 70-kilodalton S6 protein-kinase. Science 257, 973–977.
Kuo C. J., Chung J., Fiorentino D. F., Flanagan W. M., Blenis J., and Crabtree G. R. (1992) Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358, 70–73.
Ui M., Okada T., Hazeki K., and Hazeki O. (1995) Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem. Sci. 20, 303–307.
Vlahos C. J., Matter W. F., Hui K. Y., and Brown R. F. (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241–5248.
Shepherd P. R., Withers D. J., and Siddle K. (1998) Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem. J. 333, 471–490.
Wymann M. P., BulgarelliLeva G., Zvelebil M. J., Pirola L., Vanhaesebroeck B., Waterfield M. D., and Panayotou G. (1996) Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 16, 1722–1733.
Brunn G. J., Williams J., Sabers C., Wiederrecht G., Lawrence J. C. Jr., and Abraham R. T. (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY 294002. EMBO J. 15, 5256–5267.
Davis P. D., Hill C. H., Keech E., Lawton G., Nixon J. S., Sedgwick A. D., Wadsworth J., Westmacott D., and Wilkinson S. E. (1989) Potent selective inhibitors of protein kinase-C. FEBS Lett. 259, 61–63.
Toullec D., Pianetti P., Coste H., Bellevergue P., Grandperret T., Ajakane M., Baudet V., Boissin P., Boursier E., Loriolle F., Duhamel L., Charon D., and Kirilovsky J. (1991) The bisindolylmaleimide GF-109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266, 15,771–15,781.
Bradshaw D., Hill C. H., Nixon J. S., and Wilkinson S. E. (1993) Therapeutic potential of Protein kinase C inhibitors. Agents Actions 38, 135–147.
Nixon J. S., Bishop J., Bradshaw D., Davis P. D., Hill C. H., Elliott L. H., Kumar H, Lawton G., Lewis E. J., Mulqueen M., Westmacott D., Wadworth J., and Wilkinson S. E. (1992) The design and biological properties of potent and selective inhibitors of Protein kinase C. Biochem. Soc. Trans 20, 419–425.
Alessi D. R. (1997) The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1β (Rsk-2) and p70 S6 kinase. FEBS Lett. 402, 121–123.
Hall-Jackson C. A., Goedert M., Hedge P., and Cohen P. (1999) Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 18, 2047–2054.
Reiners J. J., Lee J. Y. Jr., Clift R. E., Dudley D. T., and Myrand S. P. (1998) PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol. Pharmacol. 53, 438–445.
DiComo C. J. and Arndt K. T. (1996) Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. Genes Dev. 10, 1904–1916.
Nakanishi S., Catt K. J., and Balla T. (1995) A wortmannin-sensitive phosphatidylinositol 4-kinase that regulates hormone-sensitive pools of inositolphospholipids. Proc. Natl. Acad. Sci. USA 92, 5317–5321.
Cross M. J., Stewart A., Hodgkin M. N., Kerr D. J., and Wakelam M. J. (1995) Wormannin and its structural analog demethoxyviridin inhibit stimulated phospholipase A2 activity in swiss 3T3 cells-Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. J. Biol. Chem. 270, 25,352–25,355.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Cuenda, A., Alessi, D.R. (2000). Use of Kinase Inhibitors to Dissect Signaling Pathways. In: Walker, J.M., Keyse, S.M. (eds) Stress Response. Methods in Molecular Biology™, vol 99. Humana Press. https://doi.org/10.1385/1-59259-054-3:161
Download citation
DOI: https://doi.org/10.1385/1-59259-054-3:161
Publisher Name: Humana Press
Print ISBN: 978-0-89603-611-6
Online ISBN: 978-1-59259-054-4
eBook Packages: Springer Protocols